Itonis, Inc. Announces the Results of a Case Study Testing the Effects of Its Emesyl Nasal Relief on Severe Nausea
Posted 09:30:00 07/12/2016 by Admin
LAGUNA HILLS, CA--(Marketwired - July 12, 2016) - Itonis, Inc. (OTC PINK: ITNS)
Itonis, Inc. is pleased to announce the results of the case study in which its homeopathic EMESYL® Nausea Relief nasal spray was tested on patients with severe nausea. EMESYL® Nausea Relief contains ginger as one of its active ingredients.
Dr. K. Paul Stoller, M.D. conducted the independent case study in which he tested the acute effects of the EMESYL® Nausea Relief nasal spray on patients who presented with severe nausea. The duration of the patients' nausea symptoms ranged from two to seven hours, and the treatment consisted of one spray of EMESYL® Nausea Relief into each nostril. Upon using EMESYL® Nausea Relief nasal spray, all subjects reported feeling immediately the effects of the product, then leading to relief from nausea -- which ranged from immediate relief to feeling relief in ten minutes.
EMESYL® Nausea Relief is available for purchase online at www.emesyl.com.
"I had hypothesized that the antiemetic effects of ginger may be a result of actions on the central nervous system (CNS), and as such may be more effective if delivered directly to the CNS via a nasal spray," said Dr. Charles Hensley, the inventor and developer of EMESYL®. "Towards this end, EMESYL® Nausea Relief nasal spray was developed and tested," Dr. Hensley added, and he further said, "although large clinical studies need to follow, I am extremely encouraged by Dr. Stoller's results."
Dr. Hensley explained, "Due to EMESYL® Nausea Relief's ability to provide quick and lasting relief of nausea through bypassing the gastrointestinal system, it is apparent that the EMESYL® Nausea Relief nasal spray provides convenience to individuals suffering from nausea to treat their nausea symptoms."
About Itonis, Inc.
Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. The company also holds a licensing agreement with MyECheck Inc., which allows the company to use MyECheck's patented mobile payment application and share transaction revenue fees for point of purchase payments across various industries. Please visit www.itonisholdings.com for additional information.
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Stock Quote - ITNS
Investor RelationsItonis Holdings Company is a trade name of Itonis Inc. (OTC:ITNS), a publicly traded company.
Contact our office at (949) 200-8887 or email us at firstname.lastname@example.org for more information.
Latest Quarterly Reporthttp://www.otcmarkets.com/financialReportViewer?symbol=ITNS&id=180805